Kathleen M. Loomes, Cathie Spino, Nathan P. Goodrich, Thomas N. Hangartner, Amanda E. Marker, James E. Heubi, Binita M. Kamath, Benjamin L. Shneider, Philip Rosenthal, Paula M. Hertel, Saul J. Karpen, Jean P. Molleston, Karen F. Murray, Kathleen B. Schwarz, Robert H. Squires, Jeffrey Teckman, Yumirle P. Turmelle, Estella M. Alonso, Averell H. Sherker, John C. Magee, Ronald J. Sokol, the Childhood Liver Disease Research Network – 31 July 2018 – Osteopenia and bone fractures are significant causes of morbidity in children with cholestatic liver disease.

Ping Ye, Mei Xiang, Hua Liao, Jijun Liu, Hongbo Luo, Yayun Wang, Ling Huang, Manhua Chen, Jiahong Xia – 31 July 2018 – Nonalcoholic fatty liver disease (NAFLD), ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH), is the leading cause of chronic liver diseases. Until now, no medications for NAFLD have been approved by relevant governmental agencies. Dual‐specificity phosphatase 9 (Dusp9) is a member of the DUSP protein family. Dusp9 is expressed in insulin‐sensitive tissues, and its expression may be modified with the development of insulin resistance (IR).

Virginia Hernández‐Gea, Anna Baiges, Fanny Turon, Juan Carlos Garcia‐Pagán – 31 July 2018 – Idiopathic portal hypertension (IPH) is a rare disorder characterized by clinical portal hypertension in the absence of a recognizable cause such as cirrhosis. Laboratory tests often reveal a preserved liver function with anemia, leukopenia, and thrombocytopenia due to splenomegaly. Imaging studies reveal signs of portal hypertension, whereas liver stiffness and portal pressure values are usually normal or slightly elevated.

Pierre‐Yves Boëlle, Dominique Debray, Loic Guillot, Annick Clement, Harriet Corvol, on behalf of the French CF Modifier Gene Study Investigators – 30 July 2018 – Cystic fibrosis (CF)–related liver disease (CFLD) is a common symptom in patients with CF. However, its prevalence, risk factors, and evolution are unclear. We analyzed a large database of patients with CF to investigate the incidence of CFLD, its related risk factors, and the use and effect of ursodeoxycholic acid (UDCA) treatment.

Yuri L. Boteon, Richard W. Laing, Andrea Schlegel, Lorraine Wallace, Amanda Smith, Joseph Attard, Ricky H. Bhogal, Desley A. H. Neil, Stefan Hübscher, M. Thamara P. R. Perera, Darius F. Mirza, Simon C. Afford, Hynek Mergental – 30 July 2018 – Hypothermic oxygenated perfusion (HOPE) and normothermic perfusion are seen as distinct techniques of ex situ machine perfusion of the liver. We aimed to demonstrate the feasibility of combining both techniques and whether it would improve functional parameters of donor livers into transplant standards.

Pierre‐Yves Boëlle, Dominique Debray, Loic Guillot, Annick Clement, Harriet Corvol, on behalf of the French CF Modifier Gene Study Investigators – 30 July 2018 – Cystic fibrosis (CF)–related liver disease (CFLD) is a common symptom in patients with CF. However, its prevalence, risk factors, and evolution are unclear. We analyzed a large database of patients with CF to investigate the incidence of CFLD, its related risk factors, and the use and effect of ursodeoxycholic acid (UDCA) treatment.

Chiara Mazzarelli, Mary D. Cannon, Mark Hudson, Nigel Heaton, Debashis Sarker, Pauline Kane, Alberto Quaglia, Abid Suddle – 28 July 2018

Chiara Mazzarelli, Mary D. Cannon, Mark Hudson, Nigel Heaton, Debashis Sarker, Pauline Kane, Alberto Quaglia, Abid Suddle – 28 July 2018

Ernesto Cortes, Dariusz Lachowski, Alistair Rice, Antonios Chronopoulos, Benjamin Robinson, Stephen Thorpe, David A Lee, Lucia A Possamai, Haiyun Wang, David J Pinato, Armando E. del Río Hernández – 28 July 2018 – Hepatic stellate cells (HSCs) are essential perisinusoidal cells in both healthy and diseased liver. HSCs modulate extracellular matrix (ECM) homeostasis when quiescent, but in liver fibrosis, HSCs become activated and promote excess deposition of ECM molecules and tissue stiffening via force generation and mechanosensing.

Lucy Golden‐Mason, Hugo R. Rosen – 28 July 2018